April 2011. It’s late afternoon, and my second day of the Partial Program at Beverly Hospital has wrapped up.
I’m plowing down Route 128 with a song on the radio that I don’t remember. Everything has changed, but I’m not totally sure if that’s a good or bad thing.
Sometimes we get so involved working on an initiative, it’s hard to mark our own progress.
One year ago at this time, Beacon Health Options was still drafting our suicide prevention white paper. In February 2017, Beacon released, “We Need to Talk About Suicide.”
My story is really about one of my daughters.
To protect her privacy as I tell her story, I’ll call her Elizabeth. Elizabeth has had suicidal ideations from since she was about 12 to about 17. At 4 years old, she was misdiagnosed with attention deficit hyperactivity disorder (ADHD).
Within hours of being at the Washington Hilton, I knew I was in for a special experience.
As I began to set up Beacon’s booth at the 2017 National Alliance on Mental Illness (NAMI) Annual Convention, I couldn’t help but notice the hopeful faces all around me.
The phone rings, early on a Sunday morning. I’m excited, as it is a childhood friend whom I’m really looking forward to reconnecting with; only she asks me to let my parents know that her brother committed suicide the night before.
No words can describe the pain heard and felt. Of course, as outsiders, as onlookers, our first unspoken questions are “How did this happen?” “How did he do it?”
Emergency Department (ED) “boarding” – when patients get stuck in the ED for hours, sometimes days, because there is no placement option readily available – is an issue across the country and has received much attention in Massachusetts recently.
Earlier this month, The Boston Globe published an article highlighting the fact that many of these individuals have behavioral health conditions.
As a professional observer of healthcare for the last 20 years, the relationship between Adam Smith economics and healthcare research and developments has always fascinated me.
In brief, does the dynamic of competition that drives profit-making innovation propel, or hinder, medical breakthroughs?
The National Institutes of Health (NIH) initiative around “precision medicine” – treatment that focuses on the unique genetic code of the individual and not a one-size-fits-all treatment – begs that question.
MassHealth is just weeks away from accepting applications from provider and insurance organizations to form Accountable Care Organizations (ACOs).
But what does that mean in terms of tangible impact to Beacon Health Options and companies like it, the Commonwealth, and most importantly, the member? Should we feel excited? Skeptical? Indifferent?